Bausch Health Initiates Second P-III Study for NOV03 (perfluorohexyloctane) to Treat DED Associated With MGD

November 25, 2020 Auto Bot Bausch Health, Clinical Trials, Disease, Initiates, P-III, Study, Treatment 0

Shots:

  • The enrollment of the first P-III study is currently underway & has reached 85% of its enrollment goal. In a P-II study of 336 patients, NOV03 met its 1EP of efficacy i.e. improvement of total corneal fluorescein staining over control @8wks.
  • Additionally, NOV03 showed improvement of certain symptoms, such as severity & frequency of dryness & burning/stinging of the eyes, over the entire duration of the P-II study with no notable safety events
  • NOV03 is an investigational, water-free & preservative-free solution, based on patented EyeSol technology from Novaliq

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: SPJNews

The post Bausch Health Initiates Second P-III Study for NOV03 (perfluorohexyloctane) to Treat DED Associated With MGD first appeared on PharmaShots.